Y-Biologics, Inc. (KOSDAQ:338840)
South Korea · Delayed Price · Currency is KRW 24,900
+250 (1.01%)
At close: Apr 9, 2026
Y-Biologics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -42,025 | -6,442 | -20,871 | -18,804 | -17,071 |
Depreciation & Amortization | 1,932 | 2,038 | 2,354 | 2,962 | 2,316 |
Loss (Gain) From Sale of Assets | 32.55 | 0 | -329.65 | 172.61 | -15.23 |
Stock-Based Compensation | 587.82 | 1,189 | 2,097 | 2,607 | 1,570 |
Provision & Write-off of Bad Debts | -6.09 | 300.68 | - | 425.54 | - |
Other Operating Activities | 33,330 | -1,486 | 10,736 | 207.98 | -331.6 |
Change in Accounts Receivable | 44 | 233.33 | 116.51 | -290.23 | -577.53 |
Change in Accounts Payable | -2.97 | 2.02 | 1.21 | - | - |
Change in Unearned Revenue | - | - | - | 41.03 | - |
Change in Income Taxes | - | - | -84.38 | 84.38 | - |
Change in Other Net Operating Assets | 267.51 | 21.86 | -1,627 | 2,490 | 4,941 |
Operating Cash Flow | -5,840 | -4,143 | -7,607 | -10,105 | -9,168 |
Capital Expenditures | -1,025 | -2,860 | -193.42 | -1,088 | -7,552 |
Sale of Property, Plant & Equipment | 6.68 | - | 963.98 | 237.65 | - |
Sale (Purchase) of Intangibles | -400 | - | -2.72 | -9.07 | -18.61 |
Investment in Securities | -30.92 | -2,750 | -250 | - | - |
Other Investing Activities | -220.93 | 187.84 | 3,197 | 100.51 | -325.43 |
Investing Cash Flow | -2,084 | -5,422 | 3,715 | -759.15 | -7,896 |
Long-Term Debt Issued | 35,000 | - | 500 | - | - |
Short-Term Debt Repaid | - | -2,000 | - | - | - |
Long-Term Debt Repaid | -673.85 | -193.97 | -2,781 | -803.57 | -356.89 |
Total Debt Repaid | -673.85 | -2,194 | -2,781 | -803.57 | -356.89 |
Net Debt Issued (Repaid) | 34,326 | -2,194 | -2,281 | -803.57 | -356.89 |
Issuance of Common Stock | 3,437 | 201.23 | 14,063 | 49.52 | 604.89 |
Other Financing Activities | 0 | 65 | -0 | -0 | -0 |
Financing Cash Flow | 37,763 | -1,928 | 11,782 | 6,896 | 247.99 |
Foreign Exchange Rate Adjustments | - | 40.24 | 32.59 | -290.95 | 300.15 |
Miscellaneous Cash Flow Adjustments | -0 | - | - | - | - |
Net Cash Flow | 29,839 | -11,452 | 7,922 | -4,259 | -16,516 |
Free Cash Flow | -6,865 | -7,003 | -7,801 | -11,193 | -16,720 |
Free Cash Flow Margin | -235.66% | -121.52% | -224.21% | -269.68% | -344.94% |
Free Cash Flow Per Share | -460.98 | -473.97 | -623.13 | -910.72 | -1374.20 |
Cash Interest Paid | 27.91 | 51.43 | 142.22 | 95.56 | 88.47 |
Cash Income Tax Paid | 9.19 | 61.62 | 2.89 | -7.34 | 4.1 |
Levered Free Cash Flow | -5,608 | -5,270 | -5,629 | -7,303 | -20,134 |
Unlevered Free Cash Flow | -4,821 | -5,243 | -5,539 | -7,238 | -20,062 |
Change in Working Capital | 308.54 | 257.21 | -1,593 | 2,325 | 4,364 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.